公开(公告)号：US20210340192A1

公开(公告)日：2021-11-04

申请号：US17283007

申请日：2019-10-04

申请人： UNIVERSITY OF WASHINGTON

发明人： Jeffrey Matthew NIVALA

IPC分类号： C07K14/245 ,  G01N33/543

摘要： The disclosure provides fusion reporter protein constructs and related compositions, systems, and methods for nanopore-based detection biological activity. In one aspect, the disclosure provides a fusion reporter protein comprising, in order: a blocking domain with a stably folded tertiary structure; a flexible analyte domain; and a flexible tail domain, wherein the flexible tail domain has a net negative charge. The disclosure also provides nucleic acid constructs encoding the disclosed fusion reporter protein, and vectors and cells comprising the nucleic acids. Also provided are nanopore-based systems and methods for using the disclosed fusion reporter protein constructs to detect and characterize biological activity.

公开(公告)号：US11156615B2

公开(公告)日：2021-10-26

申请号：US15776725

申请日：2016-09-02

申请人： Duke University

发明人： Homme W. Hellinga ,  Malin J. Allert

IPC分类号： G01N33/66 ,  C12Q1/54 ,  C07K14/245

摘要： The present subject matter provides glucose biosensors as well as compositions, devices, and methods comprising such biosensors.

公开(公告)号：US11147844B2

公开(公告)日：2021-10-19

申请号：US16584644

申请日：2019-09-26

申请人： Decoy Biosystems, Inc.

发明人： Michael J. Newman

IPC分类号： A61K38/00 ,  C07K14/005 ,  C07K14/245 ,  A61K35/12 ,  A61K35/74 ,  A61P31/20 ,  A61P31/18 ,  A61K38/21

摘要： The present disclosure relates generally to compositions, dosage forms, and methods for preventing and treating infections. The compositions include intact and substantially non-viable Gram-negative bacterial cells which have been treated to reduce lipopolysaccharide (LPS)-associated endotoxin activity, which surprisingly have increased activity to trigger immune cell production of cytokines.

公开(公告)号：US20210317488A1

公开(公告)日：2021-10-14

申请号：US16633461

申请日：2019-07-25

申请人： CJ CHEILJEDANG CORPORATION

发明人： Seok Myung LEE ,  Ki Yong CHEONG ,  Chang II SEO ,  Ji Sun LEE

IPC分类号： C12P13/22 ,  C07K14/245 ,  C12P13/08 ,  C12N1/20 ,  C12N15/70

摘要： Provided are a cAMP receptor protein variant, a microorganism including the same, and a method of producing an L-amino acid using the same.

公开(公告)号：US20210317402A1

公开(公告)日：2021-10-14

申请号：US17355295

申请日：2021-06-23

申请人： Inscripta, Inc.

发明人： Eric Abbate ,  Katherine Krouse ,  Nandini Krishnamurthy ,  Richard Fox ,  Daniel Held ,  Michael Clay ,  Krishna Yerramsetty

IPC分类号： C12N1/20 ,  C07K14/245

摘要： The present disclosure relates to various different types of variants in E. coli coding and noncoding regions leading to enhanced lysine production for, e.g., supplements and nutraceuticals.

公开(公告)号：US20210292376A1

公开(公告)日：2021-09-23

申请号：US17194821

申请日：2021-03-08

申请人： Oxford Nanopore Technologies Ltd. ,  VIB VZW ,  Vrije Universiteit Brussel

发明人： Stefan Howorka ,  Han Remaut ,  Lakmal Jayasinghe ,  Elizabeth Jayne Wallace ,  James Clarke ,  Richard George Hambley ,  Jonathan Bankes Pugh

IPC分类号： C07K14/245 ,  C12Q1/6869 ,  C12Q1/6874 ,  G01N27/447

摘要： The invention relates to mutant forms of CsgG. The invention also related to analyte detection and characterisation using CsgG.

公开(公告)号：US20210277071A1

公开(公告)日：2021-09-09

申请号：US16325046

申请日：2017-09-28

申请人： IPSEN BIOPHARM LIMITED

发明人： Elena FONFRIA-SUBIROS ,  David BURGIN

IPC分类号： C07K14/33 ,  C07K14/28 ,  C07K14/245

摘要： The present invention relates to hybrid neurotoxins comprising a clostridial light chain and a selective ganglioside binding moiety and to their use in therapy.

公开(公告)号：US11091774B2

公开(公告)日：2021-08-17

申请号：US15969478

申请日：2018-05-02

申请人： The Board of Trustees of the Leland Stanford Junior University

发明人： Mark A. Kay ,  Jiamiao Lu

IPC分类号： C12N15/85 ,  A61K31/713 ,  C07K14/245 ,  C12N9/12 ,  C12N9/86

摘要： Provided are nucleic acids and expression vectors having a non-silencing selectable marker gene, and methods of using the same. A subject expression vector includes an expression cassette and a non-silencing selectable marker gene. In some cases, the non-silencing selectable marker gene provides for drug resistance for prokaryotic cells, and includes a nucleotide sequence that (i) encodes a drug selectable marker protein; (ii) is operably linked to a promoter functional in prokaryotic cells, and (iii) includes an increased A/T content relative to a corresponding wild type nucleotide sequence. In some cases, the non-silencing selectable marker gene provides for drug resistance for prokaryotic cells, and includes a nucleotide sequence that (i) encodes a drug selectable marker protein; (ii) is operably linked to a promoter functional in prokaryotic cells, and (iii) has an A/T content in a range of from 52% to 70%.

公开(公告)号：US11066682B2

公开(公告)日：2021-07-20

申请号：US14007857

申请日：2012-04-02

申请人： Derek L. Greenfield ,  Louis G. Hom ,  Fernando A. Sanchez-Riera ,  Zhihao Hu ,  Vikranth Arlagadda ,  Eli S. Groban ,  Scott A. Frykman

发明人： Derek L. Greenfield ,  Louis G. Hom ,  Fernando A. Sanchez-Riera ,  Zhihao Hu ,  Vikranth Arlagadda ,  Eli S. Groban ,  Scott A. Frykman

IPC分类号： C12P7/62 ,  C12P7/64 ,  C07K14/245 ,  C07K14/195 ,  C07C31/125 ,  C07C33/02 ,  C07C53/126 ,  A61K38/00

摘要： The invention relates to compositions and methods, including polynucleotide sequences, amino acid sequences, and engineered host cells for producing fatty acids and derivates of fatty acids such as acyl-CoA, terminal olefins, fatty aldehydes, fatty alcohols, alkanes, alkenes, wax esters, ketones and internal olefins through altered expression of the transcription factor, fadR.

公开(公告)号：US11060099B2

公开(公告)日：2021-07-13

申请号：US15650285

申请日：2017-07-14

申请人： Genomatica, Inc.

发明人： Derek L. Greenfield ,  Andreas W. Schirmer ,  Elizabeth J. Clarke ,  Eli S. Groban ,  Bernardo M. Da Costa ,  Zhihao Hu ,  Kevin Holden ,  Noah Helman

IPC分类号： C12N1/21 ,  C12P7/64 ,  C07K14/195 ,  C07K14/245 ,  C12N9/16 ,  C12N15/70 ,  C12N9/04 ,  C12N9/02 ,  C12N9/10 ,  C12N9/12 ,  C12N9/88 ,  C12N9/90 ,  C12N9/00 ,  C12P7/04

摘要： The invention relates to compositions and methods, including polynucleotide sequences, amino acid sequences, recombinant host cells and recombinant host cell cultures engineered to produce fatty acid derivative compositions comprising fatty acids, fatty alcohols, fatty aldehydes, fatty esters, alkanes, terminal olefins, internal olefins or ketones. The fatty acid derivative composition is produced extracellularly with a higher titer, yield or productivity than the corresponding wild type or non-engineered host cell.